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Aims In heart failure with reduced ejection fraction (HFrEF), there is an ‘obesity paradox’, where survival is better in
patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the
effect of a sodium–glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention
of Adverse-outcomes in Heart Failure trial (DAPA-HF).
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Methods
and results
Body mass index was examined using standard categories, i.e. underweight (<18.5 kg/m2); normal weight
(18.5–24.9 kg/m2); overweight (25.0–29.9 kg/m2); obesity class I (30.0–34.9 kg/m2); obesity class II (35.0–39.9 kg/m2);
and obesity class III (≥40 kg/m2). The primary outcome in DAPA-HF was the composite of worsening heart failure
or cardiovascular death. Overall, 1348 patients (28.4%) were under/normal-weight, 1722 (36.3%) overweight, 1013
(21.4%) obesity class I and 659 (13.9%) obesity class II/III. The unadjusted hazard ratio (95% confidence interval)
for the primary outcome with obesity class 1, the lowest risk group, as reference was: under/normal-weight 1.41
(1.16–1.71), overweight 1.18 (0.97–1.42), obesity class II/III 1.37 (1.10–1.72). Patients with class I obesity were
also at lowest risk of death. The effect of dapagliflozin on the primary outcome and other outcomes did not vary
by baseline BMI, e.g. hazard ratio for primary outcome: under/normal-weight 0.74 (0.58–0.94), overweight 0.81
(0.65–1.02), obesity class I 0.68 (0.50–0.92), obesity class II/III 0.71 (0.51–1.00) (P-value for interaction = 0.79). The
mean decrease in weight at 8 months with dapagliflozin was 0.9 (0.7–1.1) kg (P< 0.001).
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Conclusion We confirmed an ‘obesity survival paradox’ in HFrEF. We showed that dapagliflozin was beneficial across the wide
range of BMI studied.
Clinical Trial Registration: ClinicalTrials.gov NCT03036124.
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Graphical Abstract
Summarising the key findings from the analyses of body mass index in the DAPA-HF trial.
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Introduction
The potential interaction between body mass index (BMI) and
the effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors
in patients with heart failure (HF) and reduced ejection fraction
(HFrEF) is of special interest given the ‘obesity survival paradox’
described in this syndrome and the fact that SGLT2 inhibitors,
unlike other effective therapies, cause a modest weight reduction.
Multiple studies have confirmed that survival in overweight and
obese patients is better than in non-obese patients, although the
explanation for this finding is uncertain and disputed.1–6 Other
studies have shown that low body weight is associated with
poorer outcome in HFrEF and weight loss (whether intentional or
unintentional) is linked to worse survival, independently of other
risk factors.7–11 Conversely, at least two of the major classes of
drugs improving survival in HF, renin–angiotensin system (RAS)
blockers and beta-blockers, either prevent weight loss or lead to
weight gain.7,11–13 The potential explanations for this are likely
multiple and complex and may include reduction in direct and
indirect cachectic effects of neurohumoral activation and associ-
ated inflammation, as well as improved haemodynamics, nutrition
and physical activity leading to gain in adipose tissue and muscle


































. not change weight in patients with HFrEF, a significant quantitative
interaction between the effect of eplerenone and adiposity has
been described, whereby the benefit of this treatment was greater
in patients with larger waist circumference.14 Consequently, we
examined the effect of a SGLT2 inhibitor, a treatment anticipated
to cause modest weight loss,15,16 according to baseline BMI in
the Dapagliflozin and Prevention of Adverse-outcomes in Heart
Failure trial (DAPA-HF). Analysis by BMI category <30 kg/m2
compared with ≥30 kg/m2 was a pre-specified subgroup analysis
in DAPA-HF but we provide more granularity about the effect
of dapagliflozin according to BMI, analysed by World Health
Organization obesity class and by using BMI as a continuous
variable.
Methods
Patients and study design
The design and primary results of the DAPA-HF trial are published.17–20
The trial was approved by an ethics committee at each participating
centre and all patients gave written informed consent.
Inclusion criteria included age of at least 18 years, New York Heart
Association (NYHA) functional classes II to IV, left ventricular ejection
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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fraction (LVEF) ≤40%, an elevated N-terminal pro-B-type natriuretic
peptide (NT-proBNP), and standard HF drug and device therapy.
Key exclusion criteria included symptoms of hypotension or a
systolic blood pressure <95 mmHg, an estimated glomerular filtration
rate (eGFR) <30 mL/min/1.73 m2 and type 1 diabetes. There were no
exclusion criteria related to BMI.
Patients were randomized to receive either dapagliflozin (10 mg
once daily) or matching placebo in a 1:1 ratio. Randomization was
stratified based on diabetes status.
Following randomization, follow-up visits took place after 14 days
and at 2, 4, 8 and 12 months, and every 4 months thereafter. Weight
was measured at each study visit without shoes and in light clothing.
Patient height was measured at visit 1, without shoes.
Baseline body mass index categories
Body mass index was calculated using measurements of height and
weight at randomization (weight in kilograms divided by height in
meters squared). In this analysis, patients were divided into BMI groups
according to World Health Organization categories, namely: under-
weight (<18.5 kg/m2); normal weight (18.5–24.9 kg/m2); overweight
(25.0–29.9 kg/m2); obesity class I (30.0–34.9 kg/m2); obesity class II
(35.0–39.9 kg/m2) and obesity class III (≥40 kg/m2).21
Outcomes
The primary outcome was a composite of cardiovascular death or a
worsening HF event (an unplanned hospitalization for HF or an urgent
visit for worsening HF requiring intravenous therapy), whichever
occurred first. Secondary outcomes included hospitalization for HF
or cardiovascular death (not reported here as essentially the same as
the primary outcome); all HF hospitalizations (first and recurrent) and
cardiovascular death; change from baseline to 8 months in the total
symptom score of the Kansas City Cardiomyopathy Questionnaire
(KCCQ-TSS); the incidence of a composite worsening renal function
endpoint (because of the small number of renal events overall, this
endpoint was not examined in these subgroups) and all-cause death.22
Change in body weight from baseline was a pre-specified exploratory
endpoint.
Pre-specified safety analyses included any serious adverse event,
adverse events leading to discontinuation of trial treatment, adverse
events of interest (i.e. volume depletion, renal events, major hypogly-
caemic events, bone fractures, diabetic ketoacidosis, amputation) and
any diagnosis of Fournier’s gangrene, as well as laboratory findings of
note. Diabetic ketoacidosis and Fournier’s gangrene were not exam-
ined here because of small numbers.
Statistical analysis
Because of the small number of patients in the underweight category,
this category was combined with the normal weight category, and
obesity class II was combined with obesity class III for the same reason,
in the main analysis.
Baseline characteristics are reported for each BMI category as
means± standard deviation (SD), median with interquartile range
(Q1–Q3) and proportions, as appropriate. A non-parametric test for
trend across groups, an extension of the Wilcoxon rank sum test, was
used to examine for variation in baseline characteristics across groups



















































































.. The effect of dapagliflozin compared to placebo on each outcome
across BMI categories was examined using Cox regression (this and
all other models described below were stratified by diabetes status).
Event rates per 100 person-years and hazard ratios (HRs) adjusted for
previous HF hospitalization (except for all-cause death) are reported
for each BMI category. Likelihood ratio tests are reported to examine
for any interaction between BMI category and treatment effect. A
semi-parametric proportional-rates model was used to estimate the
effect on recurrent HF hospitalizations.23 For analysis of change in
KCCQ-TSS the proportion of patients who had a clinically significant
(5 point) improvement or deterioration in KCCQ-TSS was calculated
and the odds ratio between patients receiving dapagliflozin vs. placebo
calculated in each BMI category. Missing KCCQ data were imputed
using multiple imputation method previously described.24 The effect
of dapagliflozin compared with placebo on each of the time to first
event endpoints over BMI as a continuous variable was modelled as a
fractional polynomial.
The relationship between BMI as a continuous variable, adjusted for
treatment and history of HF hospitalization (apart from all-cause death)
with stratification by diabetes status, and the risk of each major clinical
outcome was examined as a restricted cubic spline. This was repeated
with additional adjustment for clinical variables (including sex, age, race,
region, systolic blood pressure, eGFR, heart rate, hypertension, atrial
fibrillation, ischaemic aetiology, LVEF, NYHA class, myocardial infarc-
tion, coronary artery bypass graft and stroke) and NT-proBNP (log).
Body mass index was also considered as a categorical variable and
the HR for each outcome was examined using Cox regression with
obesity category 1 as the referent with the same adjustment as for the
restricted cubic spline analysis.
As an exploratory analysis we examined the association between a
2% reduction in BMI at 8 months and subsequent cardiovascular death
or HF hospitalization and subsequent death from any cause.
A mixed model for repeated measurement was used to examine
change in weight, systolic blood pressure, glycated haemoglobin
(HbA1c), creatinine, haematocrit and heart rate over time (adjusted
for baseline values, randomized treatment, and interaction of treat-
ment and visit, with a random intercept and slope per patient). Change
in NT-proBNP was examined using a linear regression model adjusted
for baseline NT-proBNP. The interaction between BMI group and
treatment on the occurrence of pre-specified adverse events was
tested using logistic regression with an interaction between treatment
and BMI group.
All analyses were conducted using Stata version 16 (Stata Corp.,
College Station, TX, USA) or SAS version 9.4 (SAS Institute, Cary,
NC, USA). A P-value of <0.05 was considered statistically significant.
Results
Of the 4744 patients randomized, two did not have a recorded
height and were not included in this analysis. Of the 4742 people
included, BMI ranged from 14 to 77 kg/m2 with a median value of
27 (Q1–Q3, 24–31) kg/m2 and a mean of 28.2 (SD± 6.0) kg/m2.
Overall, 87 patients (1.8%) were underweight and 1261 (26.6%)
normal weight, giving a total of 1348 patients (28.4%) who were
normal or underweight. Among the remaining patients, 1722
(36.3%) were overweight, and 1672 (35.3%) were obese; 1013
(21.4%) were in obesity class I, 441 (9.3%) in obesity class II and
218 (4.6%) in obesity class III, i.e. 659 (13.9%) were in obesity
class II or III.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Patient characteristics
Compared to individuals with a lower BMI, those in the highest BMI
category were younger, more likely to be female, and mainly white
(Table 1). Patients in the highest BMI category were more likely to
come from North America and less likely to come from Asia.
Those in the highest BMI category had a higher NYHA class
and worse KCCQ-TSS compared with the lowest BMI category,
although there was no difference in history of prior HF hospital-
ization (46.3% vs. 48.7%).
Patients with higher BMI had a higher prevalence of history
of atrial fibrillation (46.3% in the highest compared with 32.3%
in lowest BMI category) but a lower NT-proBNP level [median
1248 (Q1–Q3, 782–2153) pg/mL vs. 1736 (986–3318) pg/mL]
(to convert to ng/L, multiply by 1). They were more likely to have a
history of hypertension and higher baseline blood pressure. Obese
participants were more likely to have type 2 diabetes (58.7% vs.
32.0%), a higher HbA1c level and lower eGFR. The frequency of
coronary heart disease was not greater in patients with a higher
BMI.
Each of a diuretic, a beta-blocker and sacubitril/valsartan were
used more often in patients with a higher BMI, as was a defibril-
lating device. Conversely, digoxin was used less frequently, despite
patients with a higher BMI having a greater prevalence of atrial fib-
rillation. Among patients with type 2 diabetes at baseline, there
was greater use of insulin in patients with higher BMI (34.1% in the
highest compared with 20.2% in the lowest BMI category) but less
use of dipeptidyl peptidase-4 inhibitors (14.2% vs. 23.7%).
Relationship between baseline body mass
index and hospitalization and mortality
outcomes
The relationship between BMI modelled as a continuous variable
and the primary outcome, was a non-linear relationship, with the
lowest rate of the primary outcome in patients of BMI around
30 kg/m2 (Figure 1). A similar relationship was observed for the
other outcomes of interest, including all-cause mortality, although
the relationship between higher BMI and either type of death was
less steep than for the primary outcome or worsening HF. These
relationships between BMI and outcomes persisted in models
adjusted for other clinical variables and NT-proBNP, although, the
excess risk in the lowest BMI category was attenuated and that in
the highest BMI category accentuated.
Examination of event rates using BMI categories (rather than BMI
as a continuous variable) showed the same pattern, with the lowest
rate of primary outcome in patients in obesity class I with a rate
of 13.8 (11.3–16.8) per 100 person-years in the placebo group,
compared with a rate of 17.4 (14.8–20.4) per 100 person-years in
the normal/underweight category and a rate of 19.2 (15.5–23.7)
person-years in obesity class II/III category. A similar pattern was
seen for cardiovascular and all-cause death. The pattern for HF
hospitalization or an urgent HF visit was slightly different, with the
lowest rate in the overweight category, rather than the obesity
class I category (Table 2). The same picture was seen including



















































































.. treatment and considering underweight and obesity class III as
separate groups (online supplementary Table S1). With additional
adjustment for clinical variables and NT-proBNP, the difference
between BMI groups was attenuated. Underweight and obesity
class III remained at highest risk for mortality outcomes, while
underweight had lower rates of hospitalization for HF.
At 8 months, a reduction in BMI of >2% was associated with a
higher risk of cardiovascular death or HF hospitalization, with a
HR of 1.36 (95% CI 1.12–1.67) in the overall population. In the
placebo group, the HR was 1.50 (95% CI 1.14–1.97) and in the
dapagliflozin group it was 1.22 (95% CI 0.91–1.65) (P-value for
interaction = 0.42). For the outcome of all-cause mortality, the
HR was 1.55 (95% CI 1.21–1.99) in the overall population, 1.98
(95% CI 1.40–2.78) in the placebo group and 1.18 (0.82–1.69) in
the dapagliflozin group (P-value for interaction = 0.07).
Change in weight with dapagliflozin
across body mass index categories
Change in weight from baseline, according to baseline BMI cate-
gory, is shown in Figure 2 and online supplementary Table S2. Over-
all change in weight by randomized treatment is shown in online
supplementary Figure S1. The mean overall placebo-corrected
decrease in weight at 8 months with dapagliflozin was 0.9 (0.7–1.1)
kg (P< 0.001). BMI did not modify the effect of dapagliflozin on
weight (P-value for interaction = 0.69) (Graphical Abstract).
Change in systolic blood pressure, heart
rate, glycated haemoglobin, creatinine,
haematocrit and NT-proBNP
with dapagliflozin across body mass
index categories
Changes in systolic blood pressure, HbA1c, creatinine, haema-
tocrit and heart rate from baseline, according to baseline BMI
category and treatment assignment, are shown in online supple-
mentary Table S2 and online supplementary Figure S2. There was no
significant interaction between BMI and the effect of treatment on
systolic blood pressure, haematocrit or heart rate. Dapagliflozin
reduced HbA1c more in patients with higher BMI due to the larger
proportion of obese patients with diabetes (P-value for interac-
tion = 0.004). Obese patients had a smaller rise in creatinine
than less obese patients (P-value for interaction = 0.005) (online
supplementary Figure S2). The mean overall placebo-corrected
decrease in NT-proBNP at 8 months with dapagliflozin was 303
(150–457) pg/mL (P≤ 0.001). BMI did not modify the effect of
dapagliflozin on NT-proBNP (online supplementary Table S2).
Effect of dapagliflozin, compared
with placebo, on outcomes, according
to baseline body mass index
The effect of treatment according to baseline BMI analysed as a
categorical variable is shown in Table 2 and analysed as a continuous
variable in online supplementary Figure S3.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Patients, n 1348 1722 1013 659
BMI (kg/m2), median (IQR) 22 (21–24) 27 (26–28) 31 (30–33) 38 (36–41)
Female sex, n (%) 334 (24.8) 346 (20.1) 227 (22.4) 202 (30.7) 0.02
Age at randomization (years) 67±12 67±10 66±10 63±11 <0.001
Race, n (%)a
White 621 (46.1) 1283 (74.5) 854 (84.3) 573 (86.9) <0.001
Black or African 47 (3.5) 69 (4.0) 58 (5.7) 52 (7.9)
Asian 656 (48.7) 349 (20.3) 87 (8.6) 24 (3.6)
Other 24 (1.8) 21 (1.2) 14 (1.4) 10 (1.5)
Region, n (%)
North America 107 (7.9) 238 (13.8) 173 (17.1) 158 (24.0) <0.001
South America 200 (14.8) 307 (17.8) 182 (18.0) 127 (19.3)
Europe 397 (29.5) 833 (48.4) 574 (56.7) 350 (53.1)
Asia/Pacific 644 (47.8) 344 (20.0) 84 (8.3) 24 (3.6)
Systolic blood pressure (mmHg) 118±16 122±16 125±16 125±16 <0.001
Diastolic blood pressure (mmHg) 71±10 74±10 75±10 76±10 <0.001
Heart rate (bpm) 72±12 71±12 71±11 73±12 0.25
Creatinine (mg/dL) 1.13± 0.34 1.18± 0.33 1.23± 0.36 1.20± 0.36 <0.001
Creatinine (μmol/L) 100.4± 29.7 104.7± 29.3 108.4± 31.8 106.0± 31.5 <0.001
eGFR (mL/min/1.73 m2) 68.0± 20.2 65.3±19.0 63.6±18.8 65.8±19.4 <0.001
NT-proBNP (pg/mL), median (IQR) 1736 (986–3318) 1423 (854–2668) 1285 (799–2271) 1248 (782–2153) <0.001
ECG AF/flutter 2206 (1399–3661) 2167 (1317–3445) 1845 (1188–2826) 1619 (1120–2482) <0.001
ECG not AF/flutter 1572 (874–3176) 1271 (760–2320) 1139 (709–1985) 1109 (658–2010) <0.001
Ischaemic aetiology, n (%) 695 (51.6) 1030 (59.8) 630 (62.2) 318 (48.3) 0.62
Time from HF diagnosis, n (%) 0.07
0–3 months 44 (3.3) 49 (2.8) 33 (3.3) 24 (3.6)
>3–6 months 138 (10.2) 131 (7.6) 80 (7.9) 44 (6.7)
>6–12 months 182 (13.5) 194 (11.3) 112 (11.1) 67 (10.2)
>1–2 years 196 (14.5) 246 (14.3) 155 (15.3) 89 (13.5)
>2–5 years 304 (22.6) 402 (23.3) 242 (23.9) 157 (23.8)
>5 years 484 (35.9) 700 (40.7) 391 (38.6) 278 (42.2)
LVEF (%) 30± 7 31± 7 32± 7 31± 7 <0.001
Baseline HbA1c (%) 6.30±1.26 6.44±1.31 6.64±1.43 6.82±1.39 <0.001
Baseline HbA1c in patients with T2DM (%) 7.37±1.60 7.34±1.56 7.44±1.55 7.46±1.41 0.01
Baseline HbA1c in patients without T2DM (%) 5.72± 0.38 5.77± 0.40 5.77± 0.41 5.81± 0.38 0.008
NYHA class, n (%) <0.001
II 960 (71.2) 1194 (69.3) 651 (64.3) 396 (60.1)
III 374 (27.7) 510 (29.6) 355 (35.0) 259 (39.3)
IV 14 (1.0) 18 (1.0) 7 (0.7) 4 (0.6)
KCCQ-TSS at baseline, median (IQR) 83 (66–96) 79 (61–92) 75 (56–92) 66 (47–83) <0.001
Past medical history, n (%)
Hypertension 835 (61.9) 1277 (74.2) 836 (82.5) 572 (86.8) <0.001
Prior diagnosis of T2DM 431 (32.0) 665 (38.6) 500 (49.4) 387 (58.7) <0.001
Atrial fibrillation 435 (32.3) 672 (39.0) 406 (40.1) 305 (46.3) <0.001
Hospitalization for HF 656 (48.7) 827 (48.0) 462 (45.6) 305 (46.3) 0.15
Myocardial infarction 549 (40.7) 827 (48.0) 482 (47.6) 234 (35.5) 0.34
Stroke 139 (10.3) 170 (9.9) 99 (9.8) 58 (8.8) 0.32
COPD 169 (12.5) 197 (11.4) 123 (12.1) 96 (14.6) 0.28
PCI 408 (30.3) 657 (38.2) 372 (36.7) 187 (28.4) 0.97
CABG 184 (13.6) 313 (18.2) 209 (20.6) 93 (14.1) 0.08
Treatments, n (%)
ACE inhibitor 766 (56.8) 968 (56.2) 571 (56.4) 356 (53.9) 0.29
ARB 368 (27.3) 479 (27.8) 273 (26.9) 186 (28.2) 0.84
ARNI 93 (6.9) 191 (11.1) 129 (12.7) 94 (14.3) <0.001
Diuretic 1234 (91.5) 1597 (92.7) 964 (95.2) 637 (96.7) <0.001
Digoxin 292 (21.7) 324 (18.8) 159 (15.7) 112 (17.0) 0.001
Beta-blocker 1254 (93.0) 1663 (96.6) 987 (97.4) 652 (98.9) <0.001
MRA 961 (71.3) 1209 (70.2) 735 (72.6) 465 (70.6) 0.86
Oral anticoagulant 482 (35.8) 736 (42.7) 429 (42.3) 321 (48.7) <0.001
Antiplatelet 733 (54.4) 982 (57.0) 568 (56.1) 309 (46.9) 0.01
Statin 830 (61.6) 1194 (69.3) 715 (70.6) 437 (66.3) 0.002
Implantable cardioverter-defibrillatorb 261 (19.4) 467 (27.1) 302 (29.8) 210 (31.9) <0.001
Cardiac resynchronization therapy 88 (6.5) 129 (7.5) 84 (8.3) 52 (7.9) 0.14
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Glucose-lowering medication (in patients with history of diabetes at baseline), n/N (%)
Biguanide 206/431 (46.4) 329/665 (49.5) 274/500 (54.8) 207/387 (53.5) 0.03
Sulfonylurea 95/431 (22.0) 156/665 (23.5) 105/500 (21.0) 82/387 (21.2) 0.52
DPP-4 inhibitor 102/431 (23.7) 107/665 (16.1) 46/500 (9.2) 55/387 (14.2) <0.001
GLP-1 agonist 3/431 (0.7) 5/665 (0.8) 5/500 (1) 8/387 (2.1) 0.05
Insulin 87/431 (20.2) 165/665 (24.8) 156/500 (31.2) 132/387 (34.1) <0.001
Plus-minus values are means ± standard deviation. Percentages may not total 100 due to rounding.
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CABG, coronary artery bypass graft;
COPD, chronic obstructive pulmonary disease; DPP-4, dipeptidyl peptidase 4; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1; HbA1c, glycated
haemoglobin; HF, heart failure; IQR, interquartile range; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid
receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; T2DM, type 2 diabetes mellitus.
To convert NT-proBNP from pg/mL to ng/L, multiply by 1.
aRace was reported by the investigators.
bThis category includes either an implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.
Dapagliflozin reduced the risk of the primary outcome to a sim-
ilar extent across all BMI categories: HR (95% CI) 0.74 (0.58–0.94)
for normal/underweight; 0.81 (0.65–1.02) for overweight; 0.68
(0.50–0.92) for obesity class I and 0.71 (0.51–1.00) for obesity
class II/III category (P-value for interaction = 0.79). This was also
true for the other outcomes examined (Table 2). There was no
interaction between BMI and the effect of dapagliflozin.
Dapagliflozin increased (improved) mean KCCQ-TSS as com-
pared to placebo between baseline and 8 months, with a consistent
effect across BMI categories. Overall, the proportion of patients
with a clinically meaningful (≥5-point) improvement was larger,
and the proportion with a ≥5-point deterioration smaller, in the
dapagliflozin group, compared with the placebo group. This pattern
was consistent across BMI categories (Table 2).
Pre-specified adverse events according
to baseline body mass index category
None of the pre-specified adverse events of interest were com-
mon and none occurred at a significantly different frequency
across BMI categories or by randomized therapy in each category
(Table 3).
Discussion
The key findings of this study were that an ‘obesity survival
paradox’ persists in patients with HFrEF and that dapagliflozin was
beneficial across the wide range of BMI studied, including patients
with a normal weight or who were underweight.
In keeping with prior studies, we found that there was a
U-shaped relationship between BMI and outcomes in patients
with HFrEF with the nadir in mortality rates in the BMI range
30.0–34.9 kg/m2 and the highest risk of death in patients who were
normal or underweight. The U-shaped relationship between BMI
and outcome was attenuated but not eliminated after adjustment
for known prognostic variables including NT-proBNP. However,























































.. Although in many ways it is counterintuitive that obesity could
be advantageous for survival in HFrEF, it is also the case that
weight loss, whether voluntary or involuntary, is associated with
worse outcomes and two key treatments (RAS blockers and
beta-blockers) that improve survival prevent weight loss or lead
to gain in weight.7–14 These observations have resulted in cau-
tion in HF guidelines about treating obesity, even extending to
dietary intervention. For example, the European Society of Car-
diology guidelines on management of HF state that in patients
with ‘moderate obesity’ (BMI <35 kg/m2), weight loss cannot be
recommended.25–27 In DAPA-HF we anticipated that dapagliflozin
would lead to a modest reduction in weight, reflecting increased
urinary excretion of glucose and loss of calories.15,16 However,
the average weight reduction observed by 8 months was small (<1
kg), in keeping with the findings of prior trials using agents in this
class, although the absolute reduction was greater in patients with
a higher BMI treated for longer (approximately 1.5 kg by 16 months
in those with class II/III obesity). Despite this, we found the magni-
tude of the improvement with dapagliflozin in clinical outcomes was
consistent across the spectrum of BMI studied. Specifically, there
was no evidence of diminished benefit in patients in the lowest
BMI category, although we had few underweight patients. Similarly,
we did not observe a larger benefit in obese patients, which is
also relevant, in view of the hypothesis that the ‘obesity survival
paradox’ might be explained by a greater effect of treatment of
patients with a higher BMI, a suggestion given some credence by
the finding of more benefit from eplerenone in obese patients in
EMPHASIS-HF.14
While we did find some support for the ‘obesity survival para-
dox’ in DAPA-HF, it is also very clear that high BMI is associated
with a greater risk of non-fatal outcomes, and, to a lesser degree,
death as well. For the primary composite outcome, the event rate
was highest in patients with class II/III obesity, as was the case
for worsening HF events. Moreover, in DAPA-HF, patients with
class II/III obesity had worse symptoms, with average KCCQ-TSS
a huge 17 points lower than patients in the normal/underweight
category. As well as having worse symptoms and a higher rate of
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Risk of outcomes according to body mass index (BMI). These restricted cubic splines demonstrate the risk of each outcome
modelling BMI as a continuous variable. The baseline spline in blue is adjusted for history of heart failure (HF) hospitalization (apart from for
all-cause death), randomized treatment and stratified by diabetes status. The red spline has additional adjustment for age, sex, race, region,
systolic blood pressure, estimated glomerular filtration rate, heart rate, hypertension, atrial fibrillation, ischaemic aetiology, left ventricular
ejection fraction, New York Heart Association class, myocardial infarction, coronary artery bypass graft, stroke, and N-terminal pro-B-type
natriuretic peptide. The reference point is BMI 30 kg/m2. The shaded areas represent 95% confidence intervals (CI). The lowest risk of the
primary outcome is around 30 kg/m2. There is evidence of a U-shaped relationship seen with higher risk with both low and very high BMI. A
similar pattern is seen for the other outcomes of interest. The adjusted models show the excess risk in the lowest BMI category is attenuated
while the risk in the highest BMI categories is accentuated. CV, cardiovascular; HR, hazard ratio.
hospitalization for worsening HF, HFrEF patients with obesity also
have an increased risk of developing diabetes and other problems
including obstructive sleep apnoea and atrial fibrillation, compared
with non-obese patients.27–29 A BMI of >35 kg/m2 is generally
considered a contraindication to heart transplantation.30,31 Con-
sequently, while scientifically interesting, the ‘obesity survival
paradox’ is clinically less important that the adverse associations
of obesity, given how common obesity is compared with low
BMI. In DAPA-HF, 35% of patients were obese while only 1.8%
were underweight. This emphasizes the importance of finding safe
approaches to reducing weight in patients with HF.26,32
Study limitations
There are some limitations to our report. BMI is only one measure
of adiposity and does not distinguish well between lean and fat mass

























. based on BMI, may not accurately reflect geographic variation as
the association between BMI, percentage body fat and body fat
distribution may differ across populations, although we adjusted
for both race and region in our models.33 Waist/hip circumference
and skinfold thickness, which would give more information on body
fat distribution, were not measured in DAPA-HF. We had only 87
patients in the ‘underweight’ BMI category and clearly our findings
cannot be extrapolated to patients with a low BMI. We did not
have data on physical activity or physical fitness to relate to BMI
or the effects of treatment.34–36 Some of the weight loss seen with
dapagliflozin might be attributable to diuresis, although calorie loss
and diuresis are mechanistically intertwined with SGLT2 inhibitors.
Moreover, while the absolute reduction in weight was larger in
more obese patients, an opposite pattern was seen in reduction in
NT-proBNP, and there was no difference in change in haematocrit
by BMI class, providing some indirect evidence against a strong
association between diuresis and weight loss.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Days after randomization
Placebo
Obesity Classes II & III
Figure 2 Change in weight over time by body mass index (BMI) category. Change in weight in patients randomized to dapagliflozin and placebo
over time within each BMI category demonstrates modest weight loss regardless of baseline BMI in patients randomized to dapagliflozin. There
was no significant interaction between baseline BMI and randomized treatment on change in weight.
Table 3 Adverse events by body mass index category and randomized treatment
Adverse event Under/normal- weight Overweight Obesity class I Obesity class II/III P-value for
interaction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo Dapagliflozin Placebo Dapagliflozin Placebo Dapagliflozin Placebo Dapagliflozin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
No 676 668 855 865 500 511 337 322
Discontinuation due to adverse
event, n (%)
36 (5.3) 36 (5.4) 33 (3.9) 46 (5.3) 25 (5.0) 15 (2.9) 22 (6.5) 14 (4.3) 0.09
Volume depletion, n (%) 53 (7.8) 56 (8.4) 53 (6.2) 62 (7.2) 40 (8.0) 39 (7.6) 16 (4.7) 21 (6.5) 0.80
Renal adverse event, n (%) 55 (8.1) 36 (5.4) 53 (6.2) 56 (6.5) 35 (7.0) 32 (6.3) 27 (8.0) 29 (9.0) 0.29
Bone fracture, n (%) 14 (2.1) 19 (2.8) 16 (1.9) 18 (2.1) 11 (2.2) 5 (1.0) 9 (2.7) 7 (2.2) 0.31
Amputation, n (%) 0 (0.0) 0 (0.0) 6 (0.7) 4 (0.5) 5 (1.0) 5 (1.0) 1 (0.3) 4 (1.2) 0.23
Major hypoglycaemia, n (%) 2 (0.3) 1 (0.1) 2 (0.2) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.6) n/a
Conclusion
In conclusion, the benefit of dapagliflozin on clinical outcomes
was consistent across the spectrum of BMI. Treatment with
dapagliflozin led to a small reduction in weight across the BMI cat-
egories examined, without any safety concern.
Supplementary Information
Additional supporting information may be found online in the
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